TPX-0005 Chemical Properties

Density 

1.46±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:35.0(Max Conc. mg/mL);98.5(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);28.1(Max Conc. mM)

form 

A crystalline solid

pka

10.79±0.60(Predicted)

color 

White to off-white

InChI

InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1

InChIKey

FIKPXCOQUIZNHB-WDEREUQCSA-N

SMILES

O1C2=CC=C(F)C=C2[C@@H](C)NC2C=CN3C(N=2)=C(C=N3)C(=O)NC[C@@H]1C

TPX-0005 Usage And Synthesis

Binding Mode

The cocrystal structures of repotrectinib with TRK proteins are yet to be reported. However, a docking model with TRKA suggests that the pyrazole nitrogen forms hydrogen bonds with Met592 in the hinge area. The fluorophenyl group, positioned in a hydrophobic pocket, aligns perpendicularly to the macrocycle, and the lactam oxygen atom engages in a water-mediated hydrogen bond with Met592 in the hinge region (Figs. 1,2).

Description

Ropotrectinib (TPX-0005; TP Therapeutics, San Diego, CA, USA) is a nextgeneration ROS1 inhibitor, a novel three-dimensional macrocyle with a much smaller size (MW <370) than current ROS1 inhibitors. It was specifically designed to overcome resistance mutations. Preclinical studies have shown activity against gatekeeper and solvent mutations, including G2032R, D2033N, L2026M, S1986F/Y, L1951R, and kinases involved in bypass signaling such as focal adhesion kinase, SRC proto-oncogene, and non-receptor tyrosine kinase [102, 103].

Description

Repotrectinib, also known as TPX-0005, is a multikinase (ROS1, ALK, and TRKA/B/C) inhibitor that is tested in an ongoing first-in-human phase 1/2 trail (NCT03093116).

General Description

Class: receptor tyrosine kinase; Treatment: NSCLC; Other name: TPX-0005

Biological Activity

Repotrectinib is a potent inhibitor targeting solvent-front mutations (SFMs) of ROS1, pan-TRK, and ALK. It effectively inhibits the kinase activity of wild-type ROS1, TRKA-C, and ALK, along with their SFMs, with IC50 values ranging from 0.071 to 4.46 nM. The compound shows high potency against ROS1 and TRKA-C, with approximately 15-fold selectivity over ALK.

Clinical Use

Repotrectinib has advantage with central nervous system (CNS) penetration, aimed to target both wide-type (WT) and solvent-front mutations (SFM) kinases and other resistance mutations including ROS1-G2032R and ROS1-D2033N, TRKA-G595R, TRKB-G639R, TRKC-G623R, and ALK-G1202R.

target

Primary targets: NTRK, ROS, ALT

TPX-0005(1802220-02-5)Related Product Information

• TPX-0131
• CSF1R-IN-2
• 17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aS,11R,20aR)-
• TPX-0046
• Entrectinib
• LOXO-195
• LOXO-195
• NVP-BKM120 (Hydrochloride)
• Crizotinib
• Lorlatinib (PF-06463922)